All News
RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)
This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.
Read Article
Hard Decisions in RA (9.1.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article
Gut Microbiome Differences Antedate JIA Development
Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.
Read Article
Stable Safety Outcomes with Abatacept
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Read Article
Patient Perspectives on Telemedicine Use During the Pandemic
Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.
Read Article
Altered Gut Biome in Inflammatory Arthritis
Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear. In fact, the investigato
Read Article
WHO Safety Study of Five TNF Inhibitors
Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors.
Read Article
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
Read Article
Hold the Methotrexate for One Week
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.
Read Article
Anti-Drug Antibodies with Biologics (7.14.2023)
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
Read Article
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Read Article
ICYMI: Drug Safety Differences with New Novel Therapies in RA
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
Read Article
Gut Microbiome Alterations in Lupus Patients
Recurrent bouts of systemic lupus erythematosus, marked by the body’s immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
Read Article
What is Colchicine Worth? (6.23.2023)
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
Read Article
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
Zoster protection for JAK inhibitor patients appears achievable
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.
Read Article
Links:
Links:
